SureTrader Nadex Advertisement PGUS
Home > Boards > US Listed > Biotechs >

Rexahn Pharmaceuticals, Inc. (RNN)

RNN RSS Feed
Add RNN Price Alert      Hide Sticky   Hide Intro
Moderator: DorianGray
Search This Board: 
Last Post: 3/23/2017 11:51:26 AM - Followers: 216 - Board type: Free - Posts Today: 0



   
 



   http://www.rexahn.com/cms/    

    http://finance.yahoo.com/q/ks?s=RNN

       

About

Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. Rexahn’s clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. In preclinical studies these drug candidates are effective against multiple drug resistant cancers and have shown to increase the effectiveness of various FDA approved cancer treatments. Rexahn is also developing specific biomarker tests that will help identify which patients will be most responsive to its treatments. The Company’s nanotechnology-based drug delivery system has shown it can make FDA approved chemotherapy drugs more effective.

Our clinical development pipeline consists of three novel compounds:

Archexin® Archexin® is a unique anti-cancer drug candidate which inhibits the activated form of the cancer cell signaling protein phosphorylated-Akt1 which is only found in cancer cells and is involved in cancer cell growth, survival, angiogenesis, and drug resistance. Archexin has completed a Phase I clinical trial in cancer patients and was shown to be safe and well tolerated. The dose-limiting toxicity was grade 3 fatigue. In a small Phase IIa trial in advanced pancreatic cancer patients, Archexin in combination with gemcitabine was shown to be safe and well tolerated and demonstrated a preliminary efficacy signal with a median survival of 9.1 months. Rexahn initiated an additional Phase IIa clinical trial for Archexin in combination with everolimus to treat cancer patients with metastatic renal cell carcinoma in January 2014.

RX-3117 RX-3117 is a next generation cancer cell specific nucleoside that inhibits DNA and RNA synthesis and induces apoptotic cell death by a mechanism distinct from existing non-selective nucleoside drugs currently used to treat cancer patients. Preclinical studies have shown RX-3117 to be effective in inhibiting the growth of solid tumors in the pancreas, lung, colon, kidney and others and to be effective in gemcitabine resistant cancer cell lines. An exploratory Phase I clinical trial in cancer patients was conducted in Europe in 2012 and demonstrated that RX-3117 is orally bioavailable with no reported adverse events were reported over the dose range tested. Rexahn initiated a Phase Ib clinical trial in cancer patients with solid tumors in January 2014..

 SupinoxinTM (RX-5902) SupinoxinTM is an orally administered first-in-class small molecule that inhibits the growth of multiple types of human cancer cells through inhibition of phosphorylated p68 which is selectively expressed in cancer cells. Preclinical studies to date have shown SupinoxinTM to be effective in blocking tumor progression and metastasis for melanoma, cancers of the ovary, kidney and pancreas. A Phase I clinical trial with SupinoxinTM in cancer patients with solid tumors began in August 2013. This trial is a multi-center study, designed to evaluate the safety, tolerability, and maximal tolerated dose (MTD) and preliminary efficacy in patients with solid tumors.

These clinical development programs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.

Our strategy is to continue building a significant clinical development pipeline of innovative therapies that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company.

 

 Rexahn  Pipeline


 

Management Team



Peter Suzdak, Ph.D.
Chief Executive Officer 

Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.

Rick Soni, MBA
President and Chief Operating Officer

Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.

Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President  and Chief Financial Officer

Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University




ANALYST COVERAGE
 
Roth Capital Partners, LLC
      Joseph Pantginis, Ph.D.
646-358-1907

[email protected]

Maxim Group, LLC
Echo He, MD, Ph.D.
212-895-3718

[email protected]

H. C. Wainwright & Co., LLC
Andrew Fein
212-356-0546

[email protected]   


INVESTOR RELATIONSThe Trout Group LLC
Tricia Truehart
(646) 378-2953
[email protected]

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RNN
Current Price
Volume:
Bid Ask Day's Range
SureTrader
RNN News: Proxy Statement (definitive) (def 14a) 02/24/2017 04:27:39 PM
RNN News: Annual Report (10-k) 02/24/2017 04:19:17 PM
RNN News: Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) 02/13/2017 04:47:45 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 01/24/2017 05:53:52 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 01/24/2017 05:51:41 PM
PostSubject
#3292  Sticky Note http://oracledispatch.com/2017/03/15/epic-rise-rexahn-pharmaceuticals-inc-nysemk gsim79 03/16/17 07:31:45 AM
#3336   That's very true. I'm long through the complaints rspect 03/23/17 11:51:25 AM
#3335   You could be correct..But No stock ever goes pearsby09 03/23/17 11:50:09 AM
#3334   Look, this stock hasn't done anything. It had rspect 03/23/17 10:23:02 AM
#3333   This is a very robust stock. n3m3sis 03/23/17 08:41:37 AM
#3332   It's called consolidation. Can't be green every fuma 03/23/17 08:21:00 AM
#3331   This is way oversold, time to double down. kpisme 03/22/17 09:25:14 AM
#3330   Drum roll please.....Markets not even open for another rspect 03/22/17 06:44:04 AM
#3329   Talk about Multiple shots on goal! Multiple indications pearsby09 03/21/17 01:58:12 PM
#3328   I'll call it now......we're closing RED today. rspect 03/21/17 10:56:59 AM
#3327   What a surprise.........down down down again. rspect 03/21/17 10:10:42 AM
#3326   Consolidation before the next leg up. April 11th Valensio 03/21/17 02:18:35 AM
#3325   I know all this. Remember I said in ttubular 03/19/17 11:39:04 AM
#3324   Approval is a long way off, upcoming catalysts Vita Nova Stocks 03/19/17 11:05:13 AM
#3323   If the drug is approved only 1.50? ttubular 03/19/17 09:38:34 AM
#3322   Wouldn't be surprised to see 1.50 by summer steve7777 03/19/17 12:43:17 AM
#3321   What is your price? ttubular 03/19/17 12:28:04 AM
#3320   too the moon lol but rnn was upgraded steve7777 03/19/17 12:27:16 AM
#3319   Just dreaming if the drug got approved mon ttubular 03/19/17 12:23:15 AM
#3318   Bet the odds are in there favor of approval steve7777 03/19/17 12:22:09 AM
#3317   Take a second and read steve7777 03/19/17 12:20:36 AM
#3316   What is your guess if the drug is approved ttubular 03/18/17 10:40:30 PM
#3315   I can see that. Company looks pretty solid steve7777 03/18/17 10:11:13 PM
#3314   Let's dream a little Let's say next week we ttubular 03/18/17 12:59:43 AM
#3313   I for sure will be rooting for it rspect 03/17/17 12:09:11 PM
#3312   I think this thing getting ready for another goldismoney1 03/17/17 12:05:28 PM
#3311   I could be. Time will tell. rspect 03/17/17 12:02:12 PM
#3310   Maybe that's all it is. IDK. rspect 03/17/17 12:01:27 PM
#3309   nice. I hope u right, in at .24 goldismoney1 03/17/17 09:19:38 AM
#3308   'Invites' are just starting to go out for Lone Wolf 03/17/17 08:52:49 AM
#3307   over on stocktwits watchers has increased from 8,000 goldismoney1 03/17/17 08:36:39 AM
#3306   me too, I would love to sell some goldismoney1 03/17/17 08:33:56 AM
#3305   No prob - looks good here, RSI is Vita Nova Stocks 03/17/17 08:30:29 AM
#3304   Actually, much better explanation than mine , thanks vita goldismoney1 03/17/17 08:29:02 AM
#3303   It's called speculation, it is what moves markets. Vita Nova Stocks 03/17/17 08:22:26 AM
#3302   you have heard the old saying "buy the goldismoney1 03/17/17 08:07:43 AM
#3301   I'll put it this way, the price isn't rspect 03/17/17 06:49:31 AM
#3300   Good post on the link, I've added it DorianGray 03/17/17 02:02:31 AM
#3299   I think the price is telling you "that goldismoney1 03/16/17 09:48:02 PM
#3298   Thanks for posting, almost "all in" on this one. goldismoney1 03/16/17 09:46:03 PM
#3297   That sounds about right. It has gotten rspect 03/16/17 04:26:58 PM
#3296   I think what we're seeing is steady upward Watership 03/16/17 03:21:21 PM
#3295   Well...looks like it's about to hit a new Lone Wolf 03/16/17 01:09:39 PM
#3294   That's a good read but it still basically rspect 03/16/17 10:59:34 AM
#3293   Let's see what today brings hopefully a close ttubular 03/16/17 08:43:50 AM
#3292   http://oracledispatch.com/2017/03/15/epic-rise-rexahn-pharmaceuticals-inc-nysemk gsim79 03/16/17 07:31:45 AM
#3291   The problem with this stock is there is rspect 03/16/17 07:15:23 AM
#3290   As long as the stock price is higher ttubular 03/15/17 09:02:17 PM
#3289   * * $RNN Video Chart 03-15-17 * * ClayTrader 03/15/17 05:14:23 PM
#3288   Stellar comeback...two days running now! Lone Wolf 03/15/17 05:01:41 PM
#3287   Did u guys see that 275k buy at ttubular 03/15/17 04:20:10 PM
PostSubject